Aikido pharma has pending data results on june 4th, with strongest balance sheet in its history while trading below cash

New york, new york--(newsfile corp. - may 20, 2021) -  pcg digital -- anthony hayes is an optimist, with good reason. the ceo of aikido pharmaceuticals (nasdaq: aiki), according to the company's q1 report and a press release recently issued, is expecting positive results from human clinical trials of dual-action peptide receptor radionuclide therapy (prrt) with notable insider buying in the open market displaying his strong belief in the company's prospects.developed by weill cornell medicine...
DOMH Ratings Summary
DOMH Quant Ranking